Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]
Archives of Medical Science: Atherosclerotic DiseasesIntroduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique +8 more
doaj +3 more sources
A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions [PDF]
The Journal of Clinical InvestigationThe myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
doaj +3 more sources
Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Ahmad Masri, Iacopo Olivotto
doaj +4 more sources
Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy [PDF]
Reviews in Cardiovascular MedicineHypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals.
Farbod Sedaghat-Hamedani +2 more
doaj +2 more sources
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials [PDF]
Open HeartBackground Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman +7 more
doaj +2 more sources
Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]
Frontiers in Cardiovascular MedicineIntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada +13 more
doaj +2 more sources
Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges [PDF]
BiomoleculesHypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj +2 more sources
The cardiac myosin binding protein-C–myosin S2 interaction: modulation of cardiac contractility and its role in hypertrophic cardiomyopathy [PDF]
Journal of Molecular and Cellular Cardiology PlusHypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder caused primarily by pathogenic variants in sarcomeric genes encoding β-cardiac myosin heavy chain ( MYH7 ) and cardiac myosin binding protein-C ( MYBPC3 ; cMyBP-C).
Stephanie R. Rzewnicki +6 more
doaj +2 more sources
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy [PDF]
Journal of Cardiovascular Development and DiseaseThe management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Benedetto Ferraresi +9 more
doaj +2 more sources
Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort [PDF]
Reviews in Cardiovascular MedicineBackground: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr +7 more
doaj +2 more sources